Outcomes-based, risk-sharing agreements are an option for manufacturers seeking to mitigate additional price regulation and access restrictions proposed by payers, politicians, and other stakeholders. When it comes to implementation, nearly all stakeholders continue to be somewhat skeptical of outcomes-based contracts (OBCs).
Consultants with Charles River Associates solicited ideas and opinions of payers and drug manufacturers through separate live discussions to gain a deeper understanding of how to overcome roadblocks to OBCs. In this article, we share the ideas we heard, examine the obstacles, and provide examples of how payers and manufacturers can collaborate to share risk and improve patient outcomes.
To read the article, click the link below.
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...